These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14526211)

  • 1. AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination.
    van Ballegooijen M; Bogaards JA; Weverling GJ; Boerlijst MC; Goudsmit J
    J Acquir Immune Defic Syndr; 2003 Oct; 34(2):214-20. PubMed ID: 14526211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
    Barouch DH; Kunstman J; Kuroda MJ; Schmitz JE; Santra S; Peyerl FW; Krivulka GR; Beaudry K; Lifton MA; Gorgone DA; Montefiori DC; Lewis MG; Wolinsky SM; Letvin NL
    Nature; 2002 Jan; 415(6869):335-9. PubMed ID: 11797012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
    J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
    Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T lymphocyte responses in HIV-1 infection: implications for vaccine development.
    Brander C; Walker BD
    Curr Opin Immunol; 1999 Aug; 11(4):451-9. PubMed ID: 10448136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development?
    O'Connor D; Allen T; Watkins DI
    Immunol Lett; 2001 Nov; 79(1-2):77-84. PubMed ID: 11595292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress toward an HIV vaccine.
    Letvin NL
    Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
    Borrow P; Lewicki H; Wei X; Horwitz MS; Peffer N; Meyers H; Nelson JA; Gairin JE; Hahn BH; Oldstone MB; Shaw GM
    Nat Med; 1997 Feb; 3(2):205-11. PubMed ID: 9018240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response".
    Jamieson BD; Ibarrondo FJ; Wong JT; Hausner MA; Ng HL; Fuerst M; Price C; Shih R; Elliott J; Hultin PM; Hultin LE; Anton PA; Yang OO
    Vaccine; 2006 Apr; 24(17):3426-31. PubMed ID: 16545508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of HIV vaccines].
    Shibata R
    Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.
    Novitsky V; Rybak N; McLane MF; Gilbert P; Chigwedere P; Klein I; Gaolekwe S; Chang SY; Peter T; Thior I; Ndung'u T; Vannberg F; Foley BT; Marlink R; Lee TH; Essex M
    J Virol; 2001 Oct; 75(19):9210-28. PubMed ID: 11533184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of viral escape in HIV-1 Nef by STEP vaccination.
    Park SY; Mack WJ; Lee HY
    AIDS; 2016 Oct; 30(16):2449-2458. PubMed ID: 27427874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cytotoxic T-lymphocyte response in HIV-1 infection.
    Kalams SA; Walker BD
    Clin Lab Med; 1994 Jun; 14(2):271-99. PubMed ID: 7924192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV.
    Altes HK; Price DA; Jansen VA
    Vaccine; 2001 Oct; 20(1-2):3-6. PubMed ID: 11567737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New hope for an AIDS vaccine.
    Robinson HL
    Nat Rev Immunol; 2002 Apr; 2(4):239-50. PubMed ID: 12001995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral evolution and challenges in the development of HIV vaccines.
    Barouch DH; Letvin NL
    Vaccine; 2002 Dec; 20 Suppl 4():A66-8. PubMed ID: 12477431
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.